X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs GLENMARK PHARMA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA GLENMARK PHARMA SUN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 26.2 14.4 182.2% View Chart
P/BV x 3.8 3.8 100.7% View Chart
Dividend Yield % 0.6 0.3 189.0%  

Financials

 SUN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
GLENMARK PHARMA
Mar-17
SUN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs842993 84.8%   
Low Rs572729 78.5%   
Sales per share (Unadj.) Rs131.6325.5 40.4%  
Earnings per share (Unadj.) Rs32.739.3 83.2%  
Cash flow per share (Unadj.) Rs38.048.7 78.0%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.50.2 213.1%  
Book value per share (Unadj.) Rs152.7159.2 95.9%  
Shares outstanding (eoy) m2,399.26282.17 850.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.42.6 203.1%   
Avg P/E ratio x21.621.9 98.7%  
P/CF ratio (eoy) x18.617.7 105.2%  
Price / Book Value ratio x4.65.4 85.6%  
Dividend payout %10.75.1 210.3%   
Avg Mkt Cap Rs m1,696,877242,991 698.3%   
No. of employees `00017.513.0 135.1%   
Total wages/salary Rs m49,02316,408 298.8%   
Avg. sales/employee Rs Th18,028.37,083.9 254.5%   
Avg. wages/employee Rs Th2,798.81,265.4 221.2%   
Avg. net profit/employee Rs Th4,479.5855.1 523.9%   
INCOME DATA
Net Sales Rs m315,78491,857 343.8%  
Other income Rs m6,232374 1,667.7%   
Total revenues Rs m322,01692,230 349.1%   
Gross profit Rs m100,89320,367 495.4%  
Depreciation Rs m12,6482,644 478.4%   
Interest Rs m3,9982,373 168.5%   
Profit before tax Rs m90,47915,724 575.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m12,1163,827 316.6%   
Profit after tax Rs m78,46211,088 707.7%  
Gross profit margin %31.922.2 144.1%  
Effective tax rate %13.424.3 55.0%   
Net profit margin %24.812.1 205.8%  
BALANCE SHEET DATA
Current assets Rs m329,53768,746 479.4%   
Current liabilities Rs m178,87027,027 661.8%   
Net working cap to sales %47.745.4 105.1%  
Current ratio x1.82.5 72.4%  
Inventory Days Days7985 92.9%  
Debtors Days Days8396 87.1%  
Net fixed assets Rs m204,76624,132 848.5%   
Share capital Rs m2,399282 850.2%   
"Free" reserves Rs m363,99744,643 815.4%   
Net worth Rs m366,39744,925 815.6%   
Long term debt Rs m14,36145,363 31.7%   
Total assets Rs m614,102117,639 522.0%  
Interest coverage x23.67.6 309.9%   
Debt to equity ratio x01.0 3.9%  
Sales to assets ratio x0.50.8 65.9%   
Return on assets %13.411.4 117.4%  
Return on equity %21.424.7 86.8%  
Return on capital %24.819.1 129.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11856,152 78.6%   
Fx outflow Rs m24,4848,084 302.9%   
Net fx Rs m19,63448,068 40.8%   
CASH FLOW
From Operations Rs m70,8226,574 1,077.3%  
From Investments Rs m-42,216-7,124 592.6%  
From Financial Activity Rs m-22,8545,432 -420.8%  
Net Cashflow Rs m6,1071,992 306.5%  

Share Holding

Indian Promoters % 63.7 48.3 131.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 6.9 74.3%  
FIIs % 23.0 34.4 66.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.5 79.0%  
Shareholders   133,026 56,727 234.5%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   UNICHEM LAB  SUVEN LIFE  STERLING BIOTECH  ELDER PHARMA  ALEMBIC LTD  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ALEMBIC LTD COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS